• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Yutaka Niihara, MD, MPH

Professor of Medicine
David Geffen School of Medicine at UCLA
1124 West Carson Street C-1, Room 12
Torrance, California, United States

Dr. Niihara has been involved in patient care and research for sickle cell disease for most of his career, and is the principal inventor of the patented L-glutamine therapy for treatment of sickle cell disease in which he co-founded the bio-pharmaceutical company, Emmaus Life Sciences, Inc. It is now in phase III clinical trial involving 32 sites throughout US with FDA Drug Designation and Fast Track Designation. Additionally, his laboratory focuses on regenerative medicine using cell sheet technology. This treatment uses autologous progenitor cell sheets to repair damaged organs such as cornea epithelium and myocardium. Currently, he is the Professor of Medicine at the David Geffen School of Medicine at UCLA. His areas of research are sickle cell disease, cancer & carcinogenesis, blood & blood products & transfusions, biological markers and oncology specialized techniques in research such as red cell enzyme studies and red cell nucleotide analysis.

expertly curated content related to this topic

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.